DR-0201

Merida Biosciences has secured $121 million in Series A financing co-led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures to develop therapeutics targeting pathogenic antibodies in autoimmune diseases.

The FDA has approved Johnson & Johnson's Tremfya for moderately to severely active Crohn's disease, marking its fourth indication in the US based on robust data from phase III GALAXI and GRAVITI studies.

Sanofi has agreed to acquire Dren Bio's DR-0201, a first-in-class bispecific myeloid cell engager that induces deep B-cell depletion, for an upfront payment of $600 million.